NCT05920889View on ClinicalTrials.gov

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

October 25, 2024

Study Completion Date

October 25, 2024

Conditions
StrokeStroke, AcuteStroke, IschemicBrain Diseases
Interventions
DRUG

Semaglutide

0.5mg subcutaneous injection of the drug before or during EVT, and 7 days after the procedure. i.e. patient will receive a total of 2 injections.

Trial Locations (2)

276000

Linyi People's Hospital, Linyi

Unknown

Chinese University of Hong Kong, Hong Kong

All Listed Sponsors
collaborator

Linyi People's Hospital

OTHER

lead

Chinese University of Hong Kong

OTHER